Bristol-Myers Squibb Company [NYSE: BMY] loss -0.63% or -0.4 points to close at $63.24 with a heavy trading volume of 7747960 shares. The company report on August 12, 2020 that Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts.
Five–year commitment builds on long-standing investment in health equity.
Bristol Myers Squibb (NYSE: BMY) and the Bristol Myers Squibb Foundation announced today a combined investment of $300 million as part of a series of commitments. For Bristol Myers Squibb and the Bristol Myers Squibb Foundation, the commitments are designed to address health disparities, increase clinical trial diversity and for Bristol Myers Squibb, to increase the company’s spend with diverse suppliers and continue to increase Black/African American and Hispanic/Latino representation at all levels of the company. These commitments build on each entity’s experience addressing health disparities and, for Bristol Myers Squibb, its investments in increasing the diversity of its workforce.
It opened the trading session at $63.02, the shares rose to $63.58 and dropped to $62.90, the range by which the price of stock traded the whole day. The daily chart for BMY points out that the company has recorded -4.30% loss over the past six months. However, it is still -39.54% lower than its most recent low trading price.
If we look at the average trading volume of 14.01M shares, BMY reached to a volume of 7747960 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Bristol-Myers Squibb Company [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $71.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 28, 2020. The new note on the price target was released on April 02, 2020, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another raise to $50, while Societe Generale analysts kept a Hold rating on BMY stock.
The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.34, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 4.13. The Price to Book ratio for the last quarter was 2.92, with the Price to Cash per share for the same quarter was set at 9.52. Price to Free Cash Flow for BMY in the course of the last twelve months was 16.68 with Quick ratio for the last quarter at 1.40.
Trading performance analysis for BMY stock
Bristol-Myers Squibb Company [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.11. With this latest performance, BMY shares gained by 6.70% in over the last four-week period, additionally sinking by -4.30% over the last 6 months – not to mention a rise of 38.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 69.13, with the RSI for the last a single of trading hit 73.12, and the three-weeks RSI is set at 63.08 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 59.15, while it was recorded at 62.57 for the last single week of trading, and 60.16 for the last 200 days.
Bristol-Myers Squibb Company [BMY]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +24.63 and a Gross Margin at +65.98. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +13.15.
Return on Total Capital for BMY is now 10.67, given the latest momentum, and Return on Invested Capital for the company is 5.96. Return on Equity for this stock inclined to 10.48, with Return on Assets sitting at 4.17. When it comes to the capital structure of this company, Bristol-Myers Squibb Company [BMY] has a Total Debt to Total Equity ratio set at 92.13. Additionally, BMY Total Debt to Total Capital is recorded at 47.95, with Total Debt to Total Assets ending up at 36.58. Long-Term Debt to Equity for the company is recorded at 85.39, with the Long-Term Debt to Total Capital now at 44.44.
Reflecting on the efficiency of the workforce at the company, Bristol-Myers Squibb Company [BMY] managed to generate an average of $114,633 per employee. Receivables Turnover for the company is 3.68 with a Total Asset Turnover recorded at a value of 0.32.Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Bristol-Myers Squibb Company [BMY]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Bristol-Myers Squibb Company posted 1.17/share EPS, while the average EPS was predicted by analysts to be reported at 1.07/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 22.20%.
An analysis of insider ownership at Bristol-Myers Squibb Company [BMY]
There are presently around $107,640 million, or 77.10% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 198,903,915, which is approximately 2.075% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 170,486,576 shares of the stock with an approximate value of $10.78 billion in BMY stocks shares; and STATE STREET CORP, currently with $6.38 billion in BMY stock with ownership of nearly 1.025% of the company’s market capitalization.
Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 1,082 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 89,172,144 shares. Additionally, 965 investors decreased positions by around 131,123,643 shares, while 263 investors held positions by with 1,481,793,188 shares. The mentioned changes placed institutional holdings at 1,702,088,975 shares, according to the latest SEC report filing. BMY stock had 135 new institutional investments in for a total of 9,467,352 shares, while 119 institutional investors sold positions of 8,926,999 shares during the same period.